Analysts Set OvaScience Inc. (OVAS) Target Price at $6.90
OvaScience Inc. (NASDAQ:OVAS) has earned an average recommendation of “Hold” from the eight brokerages that are presently covering the company. One analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $6.90.
OVAS has been the topic of several research analyst reports. Zacks Investment Research lowered OvaScience from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 2nd. JMP Securities reissued a “neutral” rating on shares of OvaScience in a research report on Wednesday, August 10th. JPMorgan Chase & Co. cut their target price on OvaScience from $9.00 to $8.00 and set a “neutral” rating on the stock in a research report on Friday, August 5th. Finally, HC Wainwright reissued a “buy” rating on shares of OvaScience in a research report on Sunday, November 6th.
Shares of OvaScience (NASDAQ:OVAS) opened at 3.73 on Thursday. OvaScience has a 52-week low of $3.39 and a 52-week high of $11.66. The firm has a 50-day moving average price of $5.33 and a 200 day moving average price of $6.10. The stock’s market cap is $132.82 million.
OvaScience (NASDAQ:OVAS) last issued its earnings results on Thursday, November 3rd. The company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.08. OvaScience had a negative return on equity of 62.66% and a negative net margin of 11,642.67%. The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.25 million. During the same quarter last year, the company earned ($0.66) EPS. The business’s quarterly revenue was down 73.3% on a year-over-year basis. Analysts expect that OvaScience will post ($2.51) earnings per share for the current year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in OVAS. Nationwide Fund Advisors raised its position in OvaScience by 31.8% in the second quarter. Nationwide Fund Advisors now owns 20,068 shares of the company’s stock worth $105,000 after buying an additional 4,846 shares during the last quarter. Citadel Advisors LLC bought a new position in OvaScience during the second quarter worth about $122,000. BlackRock Advisors LLC raised its position in OvaScience by 26.2% in the third quarter. BlackRock Advisors LLC now owns 17,001 shares of the company’s stock worth $122,000 after buying an additional 3,529 shares during the last quarter. ProShare Advisors LLC raised its position in OvaScience by 28.7% in the second quarter. ProShare Advisors LLC now owns 29,507 shares of the company’s stock worth $154,000 after buying an additional 6,572 shares during the last quarter. Finally, Northern Capital Management LLC raised its position in OvaScience by 61.0% in the second quarter. Northern Capital Management LLC now owns 30,340 shares of the company’s stock worth $158,000 after buying an additional 11,500 shares during the last quarter. 79.37% of the stock is currently owned by institutional investors and hedge funds.
OvaScience Company Profile
OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.
Receive News & Stock Ratings for OvaScience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience Inc. and related stocks with our FREE daily email newsletter.